<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01868477</url>
  </required_header>
  <id_info>
    <org_study_id>CICL670A2421</org_study_id>
    <nct_id>NCT01868477</nct_id>
  </id_info>
  <brief_title>Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.</brief_title>
  <official_title>An Open-label, Phase II, Randomized, Pilot Study to Assess the Effect in Term of Erythroid Improvement of Deferasirox Combined With Erythropoietin Compared to Erythropoietin Alone in Patients With low-and Int-1-risk Myelodysplastic Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this trial is to assess the effect of treatment with deferasirox
      combined with erythropoietin vs. erythropoietin alone on erythropoiesis in patients with low-
      and int-1-risk myelodysplastic syndrome.

      The addition of deferasirox to erythropoietin could lead to a potential synergism with the
      reduction of reactive oxygen species, through both the NF-kB pathway and the control of free
      toxic iron. This may create a better environment in the bone marrow for a better response
      with erythropoietin.

      This study is designed to test in a prospective way the combination of deferasirox with
      erythropoietin in term of their effect on hematopoiesis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2014</start_date>
  <completion_date type="Actual">March 22, 2017</completion_date>
  <primary_completion_date type="Actual">March 22, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hemoglobin levels</measure>
    <time_frame>Within 12 weeks</time_frame>
    <description>Difference in proportion of patients achieving an erythroid response within 12 weeks of treatment between the two arms according to modified IWG 2006 criteria (increase in Hb ≥ 1.5 g/dL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin, platelets and neutrophil levels</measure>
    <time_frame>Within 24 weeks</time_frame>
    <description>Proportion of patients achieving a hematological response within 24 weeks of treatment with deferasirox combined with erythropoietin and erythropoietin alone (increase in hemoglobin, improvement of neutropenia and thrombocytopenia) according to modified IWG 2006 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin levels</measure>
    <time_frame>Within 24 weeks</time_frame>
    <description>Proportion of patients achieving an erythroid response according to modified IWG 2006 criteria (increase in Hb ≥ 1.5 g/dL) within 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to erythroid response</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Time to response is defined as the time from date of start of treatment to the date of event defined as the first documented response according to modified IWG 2006 criteria (increase in Hb ≥ 1.5 g/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hematologic response</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Time to response is defined as the time from date of start of treatment to the date of event defined as the first documented response (increase in hemoglobin, improvement of neutropenia and thrombocytopenia) according to modified IWG 2006 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of erythroid response</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Duration of response is defined as the time from onset of the first response to progression/relapse (decrease in Hb ≥ 1.5 g/dL from Hb value at response)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Incidence of adverse events (AEs) overall and by severity, and serious adverse events (SAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron parameters by change in serum ferritin</measure>
    <time_frame>Baseline, followed by evaluation after 1, 2, 3, 4, 5 and 6 months</time_frame>
    <description>Change in serum ferritin from baseline to every visit throughout the study in the combination arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in platelets and neutrophil levels</measure>
    <time_frame>Within 24 weeks</time_frame>
    <description>Proportion of patients achieving a hematological improvement within 24 weeks of treatment with deferasirox combined with erythropoietin and erythropoietin alone (improvement of neutropenia and thrombocytopenia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hematologic improvement</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Time to improvement is defined as the time from date of start of treatment to the date of event defined as the first documented improvement (improvement of neutropenia and thrombocytopenia)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Adult Patients With Low Risk Myelodysplastic Syndrome</condition>
  <condition>Adult Patients With Int 1-risk Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Erythropoietin alpha</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive erythropoietin 40,000 units/week. If after 4 weeks erythroid improvement is inadequate, dose will be escalated to 60,000 units/week. If after 12 weeks of treatment, erythroid improvement in inadequate, patients will be switched to the combination arm. At any time when erythroid response is achieved, erythropoietin treatment will be stopped until end of study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferasirox + Erythropoietin alpha</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive deferasirox dispersible tablet (DT) 10 mg/kg/day or deferasirox film-coated tablet (FCT) 7 mg/kg/day in combination with erythropoietin 40,000 units/week. If after 4 weeks erythroid improvement is inadequate, erythropoietin dose will be escalated to 60,000 units/week. If after 12 weeks of treatment, erythroid improvement in inadequate, patients will be discontinued from the study. At any time when erythroid response is achieved, erythropoietin treatment will be stopped until end of study. Patients will continue deferasirox treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin alpha</intervention_name>
    <arm_group_label>Erythropoietin alpha</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin alpha</intervention_name>
    <arm_group_label>Deferasirox + Erythropoietin alpha</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferasirox</intervention_name>
    <arm_group_label>Deferasirox + Erythropoietin alpha</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with low- and Int-1-risk myelodysplastic syndrome

          -  Documented diagnosis of the following:

        Myelodysplastic syndrome lasting ≥ 3 months and &lt; 3 years Disease must not be secondary to
        treatment with radiotherapy, chemotherapy, and/or immunotherapy for malignant or autoimmune
        diseases

          -  A hemoglobin &lt; 10 g/dL and ≥ 8 g/dL

          -  History of transfusions &lt; 10 RBC units and must not be RBC transfusion dependent

          -  300 ng/mL &lt; serum ferritin &lt; 1,500 ng/mL (Values within 10% difference above 1500
             ng/ml or 10% difference below 300 ng/ml may be accepted at the investigator's
             discretion.

          -  Endogenous erythropoietin levels &lt; 500 units/L

        Exclusion Criteria:

          -  Patients with MDS with isolated del(5q)

          -  Patients who had received prior EPO treatment or other recombinant growth factors
             regardless of the outcome (Patient who had received prior EPO treatment or other
             recombinant growth factors for less than 4 weeks and not within 3 months before
             screening without a documented response are allowed)

          -  Patients receiving steroids or immunosuppressive therapy for the improvement of
             hematological parameters (stable steroid treatment for adrenal failure or chronic
             medical conditions, and intermittent dexamethasone as antiemetics are allowed).

          -  B12 and folate deficient patients with and without clinical symptoms (patients could
             be rescreened after successful therapy of B12 and folate deficiency)

          -  Uncontrolled seizures or uncontrolled hypertension

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oran</city>
        <zip>31000</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sidi Bel abbes</city>
        <zip>22000</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1425DND</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>B1900AWT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lütten-Klein</city>
        <zip>18107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cagliari</city>
        <state>CA</state>
        <zip>09126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RC</state>
        <zip>89124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Badalona</city>
        <state>Catalunya</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Girona</city>
        <state>Catalunya</state>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de LLobregat</city>
        <state>Catalunya</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gothenburg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linköping</city>
        <zip>SE-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lulea</city>
        <zip>SE-971 80</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oldham</city>
        <state>Lancashire</state>
        <zip>OL1 2JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Argentina</country>
    <country>Canada</country>
    <country>China</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2013</study_first_submitted>
  <study_first_submitted_qc>May 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2013</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>myelodysplasia</keyword>
  <keyword>blood disorder</keyword>
  <keyword>cytopenias</keyword>
  <keyword>low blood counts</keyword>
  <keyword>progressive bone marrow failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 21, 2018</submitted>
    <returned>April 23, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

